PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025Nature Metabolism21 citationsOpen Access

Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses

View Full Paper
BOBrandon M. OswaldLDLisa M. DeCampJLJoseph Longo

Key Points

  • This research aims to clarify how dietary restriction (DR) alters CD8+ T cell functions to enhance anti-tumour immunity.
  • Utilized syngeneic xenograft tumour models to assess DR effects on CD8+ T cells in the tumour microenvironment.
  • Analyzed changes in T cell fate, metabolic capacity, and cytotoxic potential under dietary restriction.
  • Measured levels of ketone body oxidation and associated metabolic pathways in T cells and tumour tissues.
  • Dietary restriction reprograms CD8+ T cell fate to promote effector T cell subsets and reduce exhaustion.
  • Increased β-hydroxybutyrate levels enhance T cell oxidative metabolism and mitochondrial function.
  • DR combined with anti-PD1 immunotherapy significantly limits tumour progression and heightens T cell anti-tumour efficacy.

Abstract

Abstract Reducing calorie intake through dietary restriction (DR) slows tumour growth in mammals, yet the underlying mechanisms are poorly defined. Here, we show that DR enhances anti-tumour immunity by optimizing CD8 + T cell function within the tumour microenvironment (TME). Using syngeneic xenograft tumour models, we found that DR induces a profound reprogramming of CD8 + T cell fate in the TME, favouring the expansion of effector T cell subsets with enhanced metabolic capacity and cytotoxic potential, while limiting the accumulation of terminally exhausted T cells. This metabolic reprogramming is driven by enhanced ketone body oxidation, particularly β-hydroxybutyrate (βOHB), which is elevated in both the circulation and tumour tissues of DR-fed mice. βOHB fuels T cell oxidative metabolism under DR, increasing mitochondrial membrane potential and tricarboxylic acid cycle-dependent pathways critical for T cell effector function, including acetyl-CoA production. By contrast, T cells deficient for ketone body oxidation exhibit reduced mitochondrial function, increased exhaustion and fail to control tumour growth under DR conditions. Importantly, DR synergizes with anti-PD1 immunotherapy, further augmenting anti-tumour T cell responses and limiting tumour progression. Our findings reveal that T cell metabolic reprogramming is central to the anti-tumour effects of DR, highlighting nutritional control of CD8 + T cell fate as a key driver of anti-tumour immunity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Oswald et al. (2025) studied this question.

synapsesocial.com/papers/69401d622d562116f28f8e2chttps://doi.org/10.1038/s42255-025-01415-6
Ask AI
Helpful
Bookmark
Share
View Full Paper